SCHEMBL1853197

SCHEMBL1853197

O=C(Nc1ccccc1)c1cc2ccccc2s1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 7/20 0.70
HDAC3 O15379 1/20 0.70
HDAC4 P56524 1/20 0.70
HDAC7 Q8WUI4 1/20 0.70
HDAC2 Q92769 1/20 0.70
HDAC10 Q969S8 1/20 0.70
HDAC11 Q96DB2 1/20 0.70
HDAC8 Q9BY41 1/20 0.70
HDAC6 Q9UBN7 1/20 0.70
HDAC9 Q9UKV0 1/20 0.70
HDAC5 Q9UQL6 1/20 0.70
RAB9A P51151 4/20 0.66
NPC1 O15118 3/20 0.66
MAPT P10636 3/20 0.66
MEN1 O00255 2/20 0.66
KMT2A Q03164 2/20 0.66
LMNA P02545 1/20 0.66
GAA P10253 1/20 0.66
HTT P42858 1/20 0.66
SMN1; SMN2 Q16637 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21446862 0.90 HDAC1 (0.61) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL29815822 0.88 HDAC1 (0.62) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL6794115 0.88 HDAC1 (0.62) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL24272396 0.88 HDAC1 (0.62) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL7712103 0.88 HDAC1 (0.62) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL21446743 0.85 HDAC1 (0.59) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL8572962 0.85 HDAC6 (0.59) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL17149299 0.83 HDAC1 (0.65) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL21446740 0.83 HDAC1 (0.58) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL23258273 0.83 SENP5 (0.61) HDAC1HDAC3HDAC4HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9719183-B2 Non-cyanide gold plating bath and method for preparing non-cyanide gold plating bath KANTO GAKUIN SCHOOL CORPORATION (JP) 2017-08-01 US claimed
US-20150167191-A1 NON-CYANIDE GOLD PLATING BATH AND METHOD FOR PREPARING NON-CYANIDE GOLD PLATING BATH KANTO GAKUIN SCHOOL CORPORATION (JP) 2015-06-18 US claimed
US-9719183-B2 Non-cyanide gold plating bath and method for preparing non-cyanide gold plating bath KANTO GAKUIN SCHOOL CORPORATION (JP) 2017-08-01 US disclosed
US-20150167191-A1 NON-CYANIDE GOLD PLATING BATH AND METHOD FOR PREPARING NON-CYANIDE GOLD PLATING BATH KANTO GAKUIN SCHOOL CORPORATION (JP) 2015-06-18 US disclosed
US-8703970-B2 Compounds having photochemically removable protecting groups based on an electrocyclic reaction between a chromophore attached via an anilide group to a benzothiophene ring MARQUETTE UNIVERSITY (US) 2014-04-22 US disclosed
US-20130231484-A1 COMPOUNDS HAVING PHOTOCHEMICALLY REMOVABLE PROTECTING GROUPS BASED ON AN ELECTROCYCLIC REACTION BETWEEN A CHROMOPHORE ATTACHED VIA AN ANILIDE GROUP TO A BENZOTHIOPHENE RING MARQUETTE UNIVERSITY (US) 2013-09-05 US disclosed
EP-2323485-A1 ANTI-ALLERGEN COMBINATIONS OF CALCIUM AND LANTHANUM SALTS Janssen Pharmaceutica, N.V. (BE) 2011-05-25 EP disclosed
US-20100189648-A1 INHIBITORS FOR DISRUPTING THE INTERACTION OF UBIQUITINATION RELATED ENZYMES AND USES THEREOF HUANG LAN 2010-07-29 US disclosed
WO-2010015697-A1 ANTI-ALLERGEN COMBINATIONS OF CALCIUM AND LANTHANUM SALTS JANSSEN PHARMACEUTICA NV (BE) 2010-02-11 WO disclosed
EP-1784076-A1 IMAZALIL COMPOSITIONS COMPRISING ALKOXYLATED AMINES JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-16 EP disclosed
WO-2006021556-A1 IMAZALIL COMPOSITIONS COMPRISING ALKOXYLATED AMINES JANSSEN PHARMACEUTICA N.V. (BE) 2006-03-02 WO disclosed
US-5712304-A MICROBIOCIDES BAYER AKTIENGESELLSCHAFT (DE) 1998-01-27 US disclosed
US-5622546-A Mould-resistant emulsion paints BAYER AKTIENGESELLSCHAFT (DE) 1997-04-22 US disclosed
US-5244893-A Fungicides BAYER AKTIENGESELLSCHAFT (DE) 1993-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231484-A1 COMPOUNDS HAVING PHOTOCHEMICALLY REMOVABLE PROTECTING GROUPS BASED ON AN ELECTROCYCLIC REACTION BETWEEN A CHROMOPHORE ATTACHED VIA AN ANILIDE GROUP TO A BENZOTHIOPHENE RING ERCC4, ALAD, ALKBH2 HDAC1 415/4885HDAC3 374/4885HDAC4 354/4885
US-20100189648-A1 INHIBITORS FOR DISRUPTING THE INTERACTION OF UBIQUITINATION RELATED ENZYMES AND USES THEREOF MDM2, UBE2N, UBE2E1 HDAC1 1359/4885HDAC3 1910/4885HDAC4 2259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.